The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from across ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

A new clinical trial tested low-dose aspirin in patients with colon and rectal cancer, also referred to as colorectal cancer. The researchers wanted to see if taking aspirin daily could help prevent ...

A research team has developed an approach to significantly reduce the risk of cancer recurrence and metastasis after surgery, by targeting both bulk cancer cells and the elusive cancer stem cells ...

A groundbreaking study reveals that a daily low dose of aspirin can significantly reduce the risk of colorectal cancer recurrence by approximately 55% in patients with specific PI3K pathway mutations.

A common over-the-counter medication could significantly reduce the risk of colorectal cancer coming back. In a Swedish study, a low dose of aspirin was shown to slash recurrence in half for patients ...

Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Taking aspirin on a daily basis protects against the recurrence of colon cancer, a new study found. People who took aspirin every day for three years had a 55% reduced risk of colorectal cancer tumors ...

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk ...

MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...